Not yet recruiting

4

80

Europe

Grafalon, Advagraf, Envarsus, Cellcept, Myfortic, Prednisona, Tacrolimus, Concentrate for solution for infusion, Capsule, Grafalon. Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit. Intravenous Use. Neovii Biotech Gmbh, Advagraf, Envarsus, Cellcept, Myfortic, Prednisona

Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Instituto de Salud Carlos III

Subclinical inflammation, including borderline lesions (BL), is very common after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with Grafalon decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT. La inflamación subclínica, es muy frecuente tras el trasplante renal (TX), aún en los pacientes de bajo riesgo inmunológico, y puede evolucionar a lesiones crónicas tipo fibrosis intersticial/ atrofia tubular (FIAT) y deterioro de la función renal. El objetivo es determinar si el tratamiento precoz de las lesiones borderline (3 m post-TX) con Grafalon disminuye la progresión de FIAT y deterioro de la función renal comparado con la terapia convencional después de dos años de seguimiento post-TX., The aim of the clinical trial is to study whether treatment of subclinical graft inflammation with grafalon improves kidney function and graft survival. El objetivo del ensayo clínico es estudiar si el tratamiento de la inflamación subclínica del injerto con grafalon mejora la función renal y la supervivencia del injerto., Not possible to specify

 

 

Recruiting

2

60

US

Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Filgrastim-aafi, Nivestym, Fludarabine, Fluradosa, Mycophenolate Mofetil, Cellcept, MMF, Mycophenolate Sodium, ERL 080, ERL 080A, Socium Mycophenolate, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Treosulfan, 1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-, Dihydroxybusulfan, Ovastat, Treosulphan, Tresulfon

Fred Hutchinson Cancer Center, medac GmbH

Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma

12/24

12/26

Recruiting

2

60

US

Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis

Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.

Acute Myeloid Leukemia

01/26

01/26

Active, not recruiting

1

25

US

FLUDARABINE, Fludara®, CYCLOPHOSPHAMIDE, Cytoxan®, Neosar®, TBI, Melphalan, Alkeran®, L-PAM, L-Sarcolysin, Phenylalanine Mustard, Sirolimus, Rapamune, Mycophenolate mofetil, CellCept, Myfortic, RGI-2001

Zachariah Michael DeFilipp, Regimmune Corporation

GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma

10/23

10/24

Active, not recruiting

N/A

76

Canada

Conversion to Advagraf, Prograf, Cyclosporine (Neoral), Advagraf, conversion of non-immunosuppressant drugs to once daily, anti-hypertensive medications, non-immunosuppressant drugs, Conversion to once daily MPA, Mycophenolate Mofetil, Myfortic, Azathioprine, Prednisone

University of British Columbia, Astellas Pharma Canada, Inc.

End-Stage Renal Disease

08/22

12/24